Colinz Laboratories
Healthcare
531210 BSE
₹69.00
Close ·
- P/E
- Not meaningful: last twelve months’ earnings are mostly a one-off item
Close 4 Nov 2026 ₹69.00 +29.19 +73.3% 1Y
Start ₹39.81
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures at the close · EPS basis: Standalone · TTM
- ROCE
- 7.20%
- Debt to Equity
- 0.04
- EPS (TTM)
- ₹11.08
- Book Value
- ₹50.45
- Market Cap
- —
- P/E (TTM)
- Not meaningful: last twelve months’ earnings are mostly a one-off item
- P/B
- 1.37
- ROE
- 5.23%
- Dividend Yield
- 0.00%
- EBITDA
- ₹90.00 L
- 52W High
- ₹87.91
- 52W Low
- ₹36.11
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
62 Good
Data confidence 98/100
Category scores
- Quality
- 59
- Good
- Returns, margins, earnings quality 22% weight
- Valuation
- 79
- Strong
- Cheap vs sector & own history 24% weight
- Growth
- 26
- Poor
- Sales & profit trajectory 9% weight
- Financial Health
- 76
- Strong
- Solvency, leverage, coverage 9% weight
- Momentum
- 86
- Strong
- Trend strength, vol-adjusted 12% weight
- Ownership
- 50
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
2- Company has reduced debt.
- Company is almost debt free.
Weaknesses
4- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -15.4%
- The company has delivered a poor sales growth of -0.07% over past five years.
- Company has a low return on equity of 5.41% over last 3 years.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Bearish | 8 | 5 | 6 |
| Oscillators | Neutral | 2 | 5 | 2 |
| Moving Averages | Strong Bearish | 6 | 0 | 4 |
Oscillators
Neutral
Bearish
2
Neutral
5
Bullish
2
Overall
Bearish
Bearish
8
Neutral
5
Bullish
6
Moving Averages
Strong Bearish
Bearish
6
Neutral
0
Bullish
4
Key readings
- RSI (14)
- 47.31
- Neutral
- MACD (12,26,9)
- −1.10
- Bullish
- SMA (50)
- 71.82
- Bearish
- SMA (200)
- 61.98
- Bullish
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 10Y | −2.73% |
|---|---|
| 5Y | −0.07% |
| 3Y | −4.95% |
| 1Y | −5.97% |
| TTM | −8.50% |
Net profit
| 10Y | +18.94% |
|---|---|
| 5Y | +19.42% |
| 3Y | +3.50% |
| 1Y | +2.00% |
| TTM | +481.25% |
Operating cash flow
| 10Y | +15.92% |
|---|---|
| 5Y | +3.29% |
| 3Y | +85.18% |
| 1Y | Turned positive |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | +1.28 pp |
|---|---|
| 5Y | +1.32 pp |
| 3Y | −1.97 pp |
| 1Y | −0.66 pp |
| TTM | −1.72 pp |
Revenue by year
| Mar 2017 | ₹8.05 Cr |
|---|---|
| Mar 2018 | ₹7.83 Cr |
| Mar 2019 | ₹7.59 Cr |
| Mar 2020 | ₹7.53 Cr |
| Mar 2021 | ₹6.16 Cr |
| Mar 2022 | ₹6.97 Cr |
| Mar 2023 | ₹7.15 Cr |
| Mar 2024 | ₹7.03 Cr |
| Mar 2025 | ₹6.53 Cr |
| Mar 2026 | ₹6.14 Cr |
Net profit by year
| Mar 2017 | ₹0.14 Cr |
|---|---|
| Mar 2018 | ₹0.23 Cr |
| Mar 2019 | ₹0.12 Cr |
| Mar 2020 | ₹0.13 Cr |
| Mar 2021 | ₹0.21 Cr |
| Mar 2022 | ₹0.34 Cr |
| Mar 2023 | ₹0.46 Cr |
| Mar 2024 | ₹0.49 Cr |
| Mar 2025 | ₹0.50 Cr |
| Mar 2026 | ₹0.51 Cr |
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.9 | 1.79 | 1.71 | 1.63 | 1.75 | 1.86 | 1.47 | 1.45 | 1.57 | 1.39 | 1.43 | 1.75 | 1.24 |
| Expenses | 1.74 | 1.67 | 1.57 | 1.51 | 1.59 | 1.69 | 1.4 | 1.35 | 1.44 | 1.31 | 1.33 | 1.66 | 1.18 |
| Operating Profit | 0.16 | 0.12 | 0.14 | 0.12 | 0.16 | 0.17 | 0.07 | 0.1 | 0.13 | 0.08 | 0.1 | 0.09 | 0.06 |
| OPM % | 8.42% | 6.7% | 8.19% | 7.36% | 9.14% | 9.14% | 4.76% | 6.9% | 8.28% | 5.76% | 6.99% | 5.14% | 4.84% |
| Other Income | 0.04 | 0.08 | 0.05 | 0.11 | 0.07 | 0.08 | 0.08 | 0.08 | 0.08 | 0.16 | 0.08 | 0.17 | 2.89 |
| Interest | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Depreciation | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
| PBT | 0.16 | 0.16 | 0.15 | 0.19 | 0.19 | 0.21 | 0.11 | 0.13 | 0.16 | 0.19 | 0.13 | 0.21 | 2.9 |
| Tax % | 18.75% | 25% | 26.67% | 31.58% | 26.32% | 23.81% | 45.45% | −23.08% | 25% | 26.32% | 30.77% | 19.05% | 17.24% |
| Net Profit | 0.12 | 0.12 | 0.11 | 0.14 | 0.14 | 0.16 | 0.05 | 0.15 | 0.12 | 0.14 | 0.08 | 0.17 | 2.4 |
| EPS (₹) | 0.48 | 0.48 | 0.44 | 0.56 | 0.56 | 0.64 | 0.2 | 0.6 | 0.48 | 0.56 | 0.32 | 0.67 | 9.53 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 7.88 | 8.1 | 8.05 | 7.83 | 7.59 | 7.53 | 6.16 | 6.97 | 7.15 | 7.03 | 6.53 | 6.14 | 5.81 |
| Expenses | 7.42 | 7.65 | 7.64 | 7.48 | 7.24 | 7.22 | 5.82 | 6.38 | 6.52 | 6.49 | 6.04 | 5.72 | 5.48 |
| Operating Profit | 0.46 | 0.45 | 0.41 | 0.35 | 0.35 | 0.31 | 0.34 | 0.59 | 0.63 | 0.54 | 0.49 | 0.42 | 0.33 |
| OPM % | 5.84% | 5.56% | 5.09% | 4.47% | 4.61% | 4.12% | 5.52% | 8.46% | 8.81% | 7.68% | 7.5% | 6.84% | 5.68% |
| Other Income | 0.1 | 0.1 | 0.09 | 0.1 | 0.12 | 0.13 | 0.19 | 0.17 | 0.15 | 0.28 | 0.3 | 0.48 | 3.3 |
| Interest | 0.12 | 0.12 | 0.12 | 0.08 | 0.1 | 0.07 | 0.09 | 0.08 | 0.05 | 0.04 | 0.04 | 0.05 | 0.04 |
| Depreciation | 0.3 | 0.28 | 0.27 | 0.22 | 0.22 | 0.19 | 0.19 | 0.2 | 0.13 | 0.13 | 0.13 | 0.16 | 0.16 |
| PBT | 0.14 | 0.15 | 0.11 | 0.15 | 0.15 | 0.18 | 0.25 | 0.48 | 0.6 | 0.65 | 0.62 | 0.69 | 3.43 |
| Tax % | 35.71% | 40% | −27.27% | −53.33% | 26.67% | 27.78% | 16% | 29.17% | 23.33% | 26.15% | 20.97% | 24.64% | — |
| Net Profit | 0.1 | 0.09 | 0.14 | 0.23 | 0.12 | 0.13 | 0.21 | 0.34 | 0.46 | 0.49 | 0.5 | 0.51 | 2.79 |
| EPS (₹) | 0.22 | 0.2 | 0.31 | 0.5 | 0.26 | 0.28 | 0.46 | 0.74 | 1.83 | 1.95 | 1.98 | 2.02 | 11.08 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.54 | 3.54 | 3.54 | 3.54 | 3.54 | 3.54 | 3.55 | 3.55 | 2.52 | 2.52 | 2.52 | 2.52 |
| Reserves | 2.62 | 2.71 | 2.98 | 3.21 | 3.3 | 3.29 | 3.75 | 4.14 | 5.62 | 6.43 | 6.96 | 7.52 |
| Borrowings | 2.53 | 1.8 | 0.76 | 0.42 | 0.68 | 0.38 | 0.99 | 0.48 | 0.27 | 0.57 | 0.64 | 0.39 |
| Other Liabilities | 1.97 | 1.7 | 2.4 | 2.42 | 1.65 | 1.6 | 1.81 | 1.76 | 1.82 | 1.84 | 1.7 | 2.35 |
| Total Liabilities | 10.66 | 9.75 | 9.68 | 9.59 | 9.17 | 8.81 | 10.1 | 9.93 | 10.23 | 11.36 | 11.82 | 12.78 |
| Fixed Assets | 3.16 | 2.88 | 2.63 | 2.41 | 2.21 | 2.06 | 2.03 | 1.86 | 1.71 | 1.58 | 1.7 | 1.54 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0.29 | 0.29 | 0.41 | 0.53 | 0.5 | 0.36 | 0.61 | 0.67 | 0.66 | 1.02 | 1.04 | 1.11 |
| Other Assets | 7.21 | 6.58 | 6.64 | 6.65 | 6.46 | 6.39 | 7.46 | 7.4 | 7.86 | 8.76 | 9.08 | 10.13 |
| Total Assets | 10.66 | 9.75 | 9.68 | 9.59 | 9.17 | 8.81 | 10.1 | 9.93 | 10.23 | 11.36 | 11.82 | 12.78 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 0.09 | 0.58 | 0.06 | 0.34 | 0.12 | 0.58 | 2.16 | 0.47 | 0.4 | 1.03 | −1.45 | 2.54 |
| Investing | 0.03 | 0 | −0.01 | −0.11 | −0.01 | −0.04 | −0.16 | −0.03 | 0.01 | 0.01 | −0.23 | 0.01 |
| Financing | 0.45 | −0.73 | −0.03 | 0.01 | 0.02 | 0.06 | 0.08 | 0.09 | 0.11 | 0.23 | 0.24 | 0.43 |
| Net Cash Flow | 0.57 | −0.16 | 0.02 | 0.24 | 0.12 | 0.6 | 2.07 | 0.52 | 0.52 | 1.27 | −1.45 | 2.98 |
| Free Cash Flow | 0.09 | 0.58 | 0.04 | 0.34 | 0.12 | 0.54 | 2 | 0.43 | 0.4 | 1.03 | −1.71 | 2.54 |
| CFO/OP | 26 | 136 | 22 | 106 | 43 | 210 | 659 | 105 | 89 | 224 | −253 | 650 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 62.53 | 60.83 | 66.65 | 78.31 | 80.79 | 72.22 | 77.03 | 63.36 | 57.69 | 44.65 | 36.89 | 49.93 |
| Inventory Days | 289 | 232 | 267 | 266 | 247 | 225 | 208 | 148 | 149 | 134 | 136 | 149 |
| Days Payable | 116 | 60.66 | 55.68 | 91.93 | 44.16 | 49.29 | 90 | 76.17 | 103 | 94.81 | 94.31 | 80.64 |
| Cash Conversion Cycle | 235 | 232 | 278 | 253 | 283 | 248 | 195 | 135 | 104 | 84.15 | 78.81 | 118 |
| Working Capital Days | 110 | 100 | 71.19 | 72.72 | 89.45 | 79.01 | 0 | 9.95 | 11.23 | −22.84 | 73.22 | −60.64 |
| ROCE % | 3.2% | 3.23% | 3% | 3.18% | 3.4% | 3.39% | 4.39% | 6.8% | 8.08% | 7.7% | 6.62% | 7.2% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Colinz Laboratories insights
60 extracted metrics across FY09–FY27.
Documents
- General announcements 7 Oct 2026
Frequently Asked Questions about Colinz Laboratories
What does Colinz Laboratories Ltd do?
Incorporated in 1986, Colinz Laboratories is in the business of manufacturing and trading in pharmaceutical formulations
Where is Colinz Laboratories Ltd (COLINZ) listed?
Colinz Laboratories Ltd trades under code 531210 on the BSE.
Which sector does Colinz Laboratories Ltd belong to?
Colinz Laboratories Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the 52-week high and low of Colinz Laboratories Ltd?
Over the last 52 weeks Colinz Laboratories Ltd has traded between ₹36.11 and ₹87.91 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Colinz Laboratories Ltd?
Colinz Laboratories Ltd reported a return on equity of 5.23%. Its debt-to-equity ratio is 0.04.
Company Information
Incorporated in 1986, Colinz Laboratories is in the business of manufacturing and trading in pharmaceutical formulations
Website colinz.com
Face Value ₹10
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/531210.md for Colinz Laboratories Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.